Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus 1% polidocanol for sclerosing esophageal varices

S. Kitano, H. Wada, K. Tanoue, Makoto Hashizume, N. Koyanagi, K. Sugimachi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sixty-six patients with portal hypertension and esophageal varices due to liver cirrhosis were randomized to receive either 5% ethanolamine oleate (EO) or 5% EO plus 1% polidocanol (EOP) as a sclerosant for endoscopic injection sclerotherapy (EIS). The two groups were well matched with regard to age, sex and the severity of liver disease. In no patient in the two groups was there any major complication, such as esophageal perforation or esophageal bleeding. Eradication of esophageal varices was attained with an average of 4.7 and 4.3 sessions of endoscopic injection sclerotherapy in the ethanolamine oleate and polidocanol groups, respectively. Data on one patient in the ethanolamine oleate group had to be excluded because he left the hospital after 2 sessions of endoscopic injection sclerotherapy. Esophageal ulcers occurred earlier in the polidocanol group (after an average of 2.8 weeks) than in the ethanolamine oleate group (3.8 weeks), the difference being statistically significant (P < 0.01). The rate of occurrence of esophageal stricture requiring more than 2 sessions of bougienage was significantly (P < 0.01) higher in the polidocanol group (16/33, 48%) than in the ethanolamine oleate group (4/32, 12%). This study suggests that the two sclerosants have equal efficacy for treating patients with esophageal varices. With polidocanol there was ulceration and stricture in the distal esophagus.

Original languageEnglish
Pages (from-to)546-548
Number of pages3
JournalHepato-Gastroenterology
Volume39
Issue number6
Publication statusPublished - Dec 1 1992

Fingerprint

Esophageal and Gastric Varices
Sclerotherapy
Sclerosing Solutions
Injections
Esophageal Perforation
Esophageal Stenosis
Portal Hypertension
Liver Cirrhosis
Esophagus
Ulcer
ethanolamine oleate
polidocanol
Liver Diseases
Pathologic Constriction
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Kitano, S., Wada, H., Tanoue, K., Hashizume, M., Koyanagi, N., & Sugimachi, K. (1992). Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus 1% polidocanol for sclerosing esophageal varices. Hepato-Gastroenterology, 39(6), 546-548.

Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus 1% polidocanol for sclerosing esophageal varices. / Kitano, S.; Wada, H.; Tanoue, K.; Hashizume, Makoto; Koyanagi, N.; Sugimachi, K.

In: Hepato-Gastroenterology, Vol. 39, No. 6, 01.12.1992, p. 546-548.

Research output: Contribution to journalArticle

Kitano, S, Wada, H, Tanoue, K, Hashizume, M, Koyanagi, N & Sugimachi, K 1992, 'Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus 1% polidocanol for sclerosing esophageal varices', Hepato-Gastroenterology, vol. 39, no. 6, pp. 546-548.
Kitano, S. ; Wada, H. ; Tanoue, K. ; Hashizume, Makoto ; Koyanagi, N. ; Sugimachi, K. / Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus 1% polidocanol for sclerosing esophageal varices. In: Hepato-Gastroenterology. 1992 ; Vol. 39, No. 6. pp. 546-548.
@article{8e5e4191391044ea963c736e72d812e2,
title = "Comparative effects of 5{\%} ethanolamine oleate versus 5{\%} ethanolamine oleate plus 1{\%} polidocanol for sclerosing esophageal varices",
abstract = "Sixty-six patients with portal hypertension and esophageal varices due to liver cirrhosis were randomized to receive either 5{\%} ethanolamine oleate (EO) or 5{\%} EO plus 1{\%} polidocanol (EOP) as a sclerosant for endoscopic injection sclerotherapy (EIS). The two groups were well matched with regard to age, sex and the severity of liver disease. In no patient in the two groups was there any major complication, such as esophageal perforation or esophageal bleeding. Eradication of esophageal varices was attained with an average of 4.7 and 4.3 sessions of endoscopic injection sclerotherapy in the ethanolamine oleate and polidocanol groups, respectively. Data on one patient in the ethanolamine oleate group had to be excluded because he left the hospital after 2 sessions of endoscopic injection sclerotherapy. Esophageal ulcers occurred earlier in the polidocanol group (after an average of 2.8 weeks) than in the ethanolamine oleate group (3.8 weeks), the difference being statistically significant (P < 0.01). The rate of occurrence of esophageal stricture requiring more than 2 sessions of bougienage was significantly (P < 0.01) higher in the polidocanol group (16/33, 48{\%}) than in the ethanolamine oleate group (4/32, 12{\%}). This study suggests that the two sclerosants have equal efficacy for treating patients with esophageal varices. With polidocanol there was ulceration and stricture in the distal esophagus.",
author = "S. Kitano and H. Wada and K. Tanoue and Makoto Hashizume and N. Koyanagi and K. Sugimachi",
year = "1992",
month = "12",
day = "1",
language = "English",
volume = "39",
pages = "546--548",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "6",

}

TY - JOUR

T1 - Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus 1% polidocanol for sclerosing esophageal varices

AU - Kitano, S.

AU - Wada, H.

AU - Tanoue, K.

AU - Hashizume, Makoto

AU - Koyanagi, N.

AU - Sugimachi, K.

PY - 1992/12/1

Y1 - 1992/12/1

N2 - Sixty-six patients with portal hypertension and esophageal varices due to liver cirrhosis were randomized to receive either 5% ethanolamine oleate (EO) or 5% EO plus 1% polidocanol (EOP) as a sclerosant for endoscopic injection sclerotherapy (EIS). The two groups were well matched with regard to age, sex and the severity of liver disease. In no patient in the two groups was there any major complication, such as esophageal perforation or esophageal bleeding. Eradication of esophageal varices was attained with an average of 4.7 and 4.3 sessions of endoscopic injection sclerotherapy in the ethanolamine oleate and polidocanol groups, respectively. Data on one patient in the ethanolamine oleate group had to be excluded because he left the hospital after 2 sessions of endoscopic injection sclerotherapy. Esophageal ulcers occurred earlier in the polidocanol group (after an average of 2.8 weeks) than in the ethanolamine oleate group (3.8 weeks), the difference being statistically significant (P < 0.01). The rate of occurrence of esophageal stricture requiring more than 2 sessions of bougienage was significantly (P < 0.01) higher in the polidocanol group (16/33, 48%) than in the ethanolamine oleate group (4/32, 12%). This study suggests that the two sclerosants have equal efficacy for treating patients with esophageal varices. With polidocanol there was ulceration and stricture in the distal esophagus.

AB - Sixty-six patients with portal hypertension and esophageal varices due to liver cirrhosis were randomized to receive either 5% ethanolamine oleate (EO) or 5% EO plus 1% polidocanol (EOP) as a sclerosant for endoscopic injection sclerotherapy (EIS). The two groups were well matched with regard to age, sex and the severity of liver disease. In no patient in the two groups was there any major complication, such as esophageal perforation or esophageal bleeding. Eradication of esophageal varices was attained with an average of 4.7 and 4.3 sessions of endoscopic injection sclerotherapy in the ethanolamine oleate and polidocanol groups, respectively. Data on one patient in the ethanolamine oleate group had to be excluded because he left the hospital after 2 sessions of endoscopic injection sclerotherapy. Esophageal ulcers occurred earlier in the polidocanol group (after an average of 2.8 weeks) than in the ethanolamine oleate group (3.8 weeks), the difference being statistically significant (P < 0.01). The rate of occurrence of esophageal stricture requiring more than 2 sessions of bougienage was significantly (P < 0.01) higher in the polidocanol group (16/33, 48%) than in the ethanolamine oleate group (4/32, 12%). This study suggests that the two sclerosants have equal efficacy for treating patients with esophageal varices. With polidocanol there was ulceration and stricture in the distal esophagus.

UR - http://www.scopus.com/inward/record.url?scp=0027081559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027081559&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 546

EP - 548

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 6

ER -